First, it interferes with its own degradation via this pathway, resulting in TDP-43 accumulation. Second, it affects vacuolar proteolytic activity, which requires endosomal-vacuolar trafficking. We speculate that the latter contributes to aberrant autophagy. In sum, we propose that ameliorating endolysosomal pathway activity enhances cell survival in TDP-43-associated diseases.
The accumulation of protein aggregates in neurons is a typical pathological hallmark of the motor neuron disease amyotrophic lateral sclerosis (ALS) and of frontotemporal dementia (FTD). In many cases, these aggregates are composed of the 43 kDa TAR DNA-binding protein (TDP-43). Using a yeast model for TDP-43 pro-
teinopathies, we observed that the vacuole (the yeast equivalent of lysosomes) markedly contributed to the degradation of TDP-43. This clearance occurred via TDP-43-containing vesicles fusing with the vacuole through the concerted action of the endosomalvacuolar (or endolysosomal) pathway and autophagy. In line with its dominant role in the clearance of TDP-43, endosomal-vacuolar pathway activity protected cells from the detrimental effects of TDP-43. In contrast, enhanced autophagy contributed to TDP-43 cytotoxicity, despite being involved in TDP-43 degradation. TDP-43's interference with endosomal-vacuolar pathway activity may have two deleterious consequences. First, it interferes with its own degradation via this pathway, resulting in TDP-43 accumulation. Second, it affects vacuolar proteolytic activity, which requires endosomal-vacuolar trafficking. We speculate that the latter contributes to aberrant autophagy. In sum, we propose that ameliorating endolysosomal pathway activity enhances cell survival in TDP-43-associated diseases.
Our study highlights the pivotal role of endolysosomal pathway activity in TDP-43 proteinopathies. Whereas previous studies focused on the role of autophagy in the clearance of cytotoxic TDP-43, we propose that the endolysosomal pathway is more important than autophagy for the survival of cells accumulating detrimental TDP-43. In both pathways, protein substrates (such as TDP-43) are sequestered into vesicles, either multivesicular bodies (MVBs) or autophagosomes ( Figure 1 ). These vesicles fuse with the lysosomal membrane and subsequently release their content into the lysosomal lumen, where protein degradation occurs via proteases such as Pep4/Cathepsin D. Both vesicular pathways are interconnected. In mammalian cells (but not in yeast), some MVBs fuse with autophagosomes, leading to the formation of amphisomes which then fuse with lysosomes. Moreover, the endolysosomal pathway is required for directing important lysosomal proteases, thus decisively contributing to proteolytic capacity of this organelle.
Our study raises a number of questions regarding TDP-43 degradation and cytotoxicity. For instance, in cells accumulating cytoplasmic TDP-43, different types of potentially cytotoxic TDP-43 species can be expected, e.g., mon- 
What is the molecular machinery that determines whether TDP-43 is degraded via the endosomal-vacuolar pathway or via autophagy (or via the ubiquitin-proteasome system)?
It is tempting to speculate that the ubiquitylation pattern of TDP-43 plays an important role. Lysine 63 (K63) polyubiquitin chains could favor the endosomal-vacuolar pathway, while K48 polyubiquitin chains could facilitate degradation via the proteasome, and both chains could be substrates for ubiquitin-dependent autophagy.
What is the molecular machinery that recruits TDP-43 into MVBs for degradation via the endosomal-vacuolar pathway?
Whereas there is a significant amount of information regarding the molecular machinery involved in recruiting protein aggregates into autophagosomes, the mechanisms that enable the recruitment of cytosolic proteins into MVBs remain largely unknown. Autophagy has been shown to be a cytoprotective mechanism to eliminate deleterious protein aggregates. Therefore, pharmacological induction of autophagy has been proposed to be an efficient mechanism to prevent neuronal loss in neurodegenerative disorders. However, this approach was not successful in our yeast TDP-43 model. In contrast, it increased cytotoxicity.
Does the observed inhibitory effect of TDP-43 on endosomal-vacuolar pathway activity and vacuolar proteolytic activity reprogram (normally cytoprotective) autophagy towards cytotoxicity?
If this holds true, a therapeutic approach that addresses both endosomal-vacuolar pathway activity and autophagic turnover should be much more effective than targeting autophagy alone.
Resolving these questions in yeast TDP-43 proteinopathy models and their validations in higher model systems (e.g., worm, fly, murine or patient-induced pluripotent stem cell-derived neuronal models) will improve our understanding of the molecular mechanisms of devastating TDP-43-associated human disorders. OPEN ACCESS | www.microbialcell.com
